Vertex reports more positive telaprevir data; Zyngenia, iPierian score new venture funds

@FierceBiotech: Actavis eyes fast-growing biosimilar market. News | Follow @FierceBiotech

 @JohnCFierce:  Biovail, Valeant plan to cut 25% of combined staffs. Get the impression from Reuters that R&D is getting downplayed. Article | Follow @JohnCFierce 

> Vertex has added yet another solid block of late-stage data to support its application for the hepatitis C treatment telaprevir. Added to standard therapy, 65 percent of the treatment-resistant patients taking telaprevir were cured of hepatitis C compared to 17 percent of the standard therapy group. An NDA for the therapy is planned for the fourth quarter and analysts give it a high chance of success. Story

> The venture arms of GlaxoSmithKline and Biogen Idec have pumped up iPierian's Series B to $28 million. Google Ventures led the round in July. Report

> Gaithersburg, MD-based Zyngenia says that it raised $15 million in new venture funds from New Enterprise Associates. The money goes toward development of a pipeline of Zybodies, a group of next-gen antibodies. Release

> Forest Laboratories says an FDA panel has unanimously recommended their new antibiotic ceftaroline. A final decision is scheduled for the fourth quarter. Story

> Belgium's Galapagos has struck a deal to acquire Glaxo's Croatian R&D center, which employs 130 staffers. Report

> A federal judge has refused to lift his injunction barring federal funding of embryonic stem cell research. Story

> Plexxikon is spelling out its development methods used for PLX4032, an experimental melanoma drug the recently delivered startling results from a small human study. Story

And Finally... The drug-resistant superbug carrying the dread NDM-1 gene has popped up in Japan. Health officials plan to find out if the bug is spreading. Story

Suggested Articles

Despite the setback, Fulcrum hailed the data as “very encouraging,” zeroing in on results from a pre-specified sensitivity analysis to make its case.

Bayer has struck a $425 million upfront deal to buy KaNDy in the belief its treatment for menopause-related hot flashes has blockbuster potential.

After its recent $4.8 billion buyout of gene therapy specialist Spark Therapeutics, Roche is now handing over one of its execs as its CMO.